Industry Reports

You have selected:


Publisher:

CBR Pharma Insights

Sort By:
Report Status:
45 Report Results
Page 1 of 2
Go To Page:
    
  Go

CBR Pharma Insights: Immunology Development Strategies – An Evolving Market with Significant Potential but with Challenging Hurdles to Overcome

$3,900.00
By:
, Published: Jul-2013

Although immunotherapy was first recognized over 100 years ago, it has only become an important therapeutic tool in recent decades. The immune system can be harnessed in one of several ways to tackle various diseases such as cancer, infection, auto-immune disease and inflammatory diseases.

The complexity of the immune system has led to some intrinsic obstacles with clinical research, particularly in relation to targeting the right genes.....

CBR Pharma Insights: The Politics of Pharma – Washington, States, and the Courts Impact on the Industry

$3,900.00
By:
, Published: Apr-2013

Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election campaigns. The November elections kept the face of Washington the same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways.<.....

CBR Pharma Insights: R&D Productivity – The State of Research and Development in the BioPharmaceutical Industry

$3,900.00
By:
, Published: Apr-2013

As blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from Is spend decreasing If spend is decreasing, what impact is this having on R&D What can be done to encourage innovation in the biotech and pharmaceutical industry Is the biotech model of R&D better for .....

CBR Pharma Insights: Companion Diagnostics - Streamlining Drug Development and Advancing Personalized Medicine

$3,900.00
By:
, Published: Apr-2013

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize r.....

CBR Pharma Insights: Biopharma M&A and Deal Making – Understanding the Latest Trends to Optimize Future Strategy

$3,900.00
By:
, Published: Mar-2013

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size .....

CBR Pharma Insights: Oncology Development Strategies - A Snapshot of the Digital Landscape of Patients and Caregivers

$3,900.00
By:
, Published: Jan-2013

The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical .....

CBR Pharma Insights: Electronic Health Records – Charting the Future of Health Care

$3,900.00
By:
, Published: Jan-2013

Electronic Health Records have been in limited use since the 1960s, but their adoption received a major boost when they became more of a focus for the US government. In 2004, President Bush put forth the goal of having every American covered by an EHR within 10 years. In 2009, President Obama added the key element of funding under the American Recovery and Reinvestment Act. The EHR Meaningful Use Incentive programs funded under the ARA were fu.....

CBR Pharma Insights: The Digital Patient - A Snapshot of the Digital Landscape of Patients and Caregivers

$3,900.00
By:
, Published: Nov-2012

The advent of mobile phones and other devices has opened up new channels for pharmaceutical marketers to reach patients and caregivers. The Pharma industry as a whole is late to the digital game so logically patients and caregivers have pre-existing expectations of the digital experience. Digital enables brands to deliver highly targeted information in a variety of forms. It creates the setting for a brand experience versus a promotional mo.....

CBR Pharma Insights: Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential – But Hurdles Still to Overcome

$3,900.00
By:
, Published: Sep-2012

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010.

Of the emerging markets, the BRIC markets offer the .....

CBR Pharma Insights: Emerging Pharmaceutical Technologies - Stem Cells

$3,900.00
By:
, Published: Aug-2012

Stem cell technology is set to play a significant role in the pharmaceutical industry of the future. The opportunities for using stem cells across drug discovery, disease research, drug development and treatments are wide-ranging, yet largely unproven at present.

Even if companies are not interested in joining the first wave of stem cell therapy developers, they need to be monitoring this sector in order to understand future competitive .....

CBR Pharma Insights: Accountable Care Organizations - A Building Block for the Future of Health Care

$3,900.00
By:
, Published: Aug-2012

The Accountable Care Act promoted ACOs through a variety of programs: Comprehensive Primary Care Initiative, Partnerships for Patients Initiative, Pioneer and Advanced Payment ACO Models and Medicare Shared Savings Program for ACOs. The central program is the Medicare Shared Savings Program, under which ACOs gradually share in the cost savings they achieve through providing coordinated and consistent care to groups of Medicare beneficiaries wh.....

CBR Pharma Insights: Clinical Development and Trial Design - Developing a Coherent Approach From Beginning to End

$3,900.00
By:
, Published: Jun-2012

A good clinical development plan will ensure success throughout the product lifecycle.

In today’s cost constrained environment, the clinical development plan can help refine the trial process, encouraging cost and time efficiencies and ensuring a streamlined process throughout.

The clinical development plan ties together all aspects of product development, enabling an incorporated approach to the clinical and commercial rationale o.....

CBR Pharma Insights: Diversification in the Pharmaceutical Industry - Essential For Survival or an Unnecessary Distraction?

$3,900.00
By:
, Published: May-2012

Pharmaceutical companies face the dual threats of industry specific difficulties driven by the innovation crisis, patent expiries and healthcare reform, coupled with the more generalized issues caused by the continuing global economic slowdown. The industry remains split on whether diversification or specialization is the key to building a successful business model in the face of these difficulties.

On one hand some companies believe tha.....

CBR Pharma Insights: The Next Generation of Pharmaceutical Marketing Strategies - Understanding All of the Strategic Considerations Needed in the Age of Multiple Stakeholders

$3,900.00
By:
, Published: Mar-2012

Pharmaceuticals save lives. They prevent more serious, life changing conditions, they prevent surgery, and they improve the quality of life for many patients. The environment in which these products are developed and commercialized is in a period of great transformation. Lacking a crystal ball, the industry as a whole is navigating through unchartered waters.

Multiple factors are driving the need for industry-wide change. One of th.....

CBR Pharma Insights: Pharmaceutical Pricing Strategies - Changing Approaches to Meet Challenging Times

$3,900.00
By:
, Published: Mar-2012

The current economic environment has created a number of challenges within the pharmaceutical market, with governments looking to reduce spending on healthcare and drugs. Consequently, prices have come under scrutiny, with many older products having discounts forced upon them and new drugs being subject to increasingly complex assessments in order to obtain the desired price.

Novel pricing policies, such as value based pricing and extern.....

CBR Pharma Insights: The Payer Landscape in the United States - The Pharmaceutical Industry Faces a Rapidly Changing Marketplace

$3,900.00
By:
, Published: Mar-2012

Managed care began to be developed as early as 1917, with both private and government payers established by the mid-1960s. Medicare and Medicaid are the major government payers, with the health care reform legislation of 2010 providing changes for both. That said, private payers, such as regionals, nationals and blues plans, may take the brunt of the reform policies put in place.

The health care reform legislation in 2010 was the product.....

CBR Pharma Insights: Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management

$3,900.00
By:
, Published: Jan-2012

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. It’s potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy.

Reformulation will continue to be a much used lifecycle management strategy, enabling companies to b.....

CBR Pharma Insights: Looking at Senior Long-term Care - Where will the Market Go?

$3,900.00
By:
, Published: Dec-2011

In the last 50 years, long-term care facilities in the US have changed significantly. Many facilities are now Continuing Care Retirement Communities (CCRCs), offering a continuum of care from Independent Living to Assisted Living to Skilled Nursing. Memory Care facilities, for those with Alzheimer’s Disease or Dementia are often separate facilities, but may be part of a larger CCRC campus.

Long-term care is becoming increasingly importan.....

CBR Pharma Insights: Risk Evaluation and Mitigation Strategies - Adaptation in an Evolving System

$3,900.00
By:
, Published: Oct-2011

The Food and Drug Administration has been looking at ways to mitigate risk on certain pharmaceutical products since the 1970s. As an evolution of this process, the agency established the Risk Evaluation and Mitigation Strategies (REMS) program in 2008.

Products can be approved with a Medication Guide only REMS, a Communication Plan REMS – which incorporates a Medication Guide together with educational materials for providers or it can re.....

CBR Pharma Insights: The Impact of Generics on Pharmaceutical Growth Opportunities - A Growing Threat that Offers Future Opportunities

$3,900.00
By:
, Published: Oct-2011

While generic penetration has been on the rise in the major developed markets for some time, the current and continuing difficult economic environment is stimulating political and payer actions to accelerate the trend.

Combined with this, pharma is experiencing a wave of blockbuster patent expiries, with almost $30 billion in US sales (at 2010 levels) exposed by the largest 10 drugs which are expected to experience generic competition fo.....

CBR Pharma Insights: Accelerating Drugs to Market - In Search of Opportunity Along the Drug Development & Approval Pathway

$3,900.00
By:
, Published: Sep-2011

The commercial life of a drug and the sales trajectory achieved are dependent on a multitude of factors. One critical factor in achieving success is the ability to bring a product to market quickly to gain competitive advantages and to start recouping development costs. From product concept to market, there are a number of potential areas of opportunity for accelerating a drug through to FDA approval. Many initiatives tie to scientific and tec.....

CBR Pharma Insights: Pharmaceutical Sales Force Effectiveness - Rethinking the Current Sales Model

$3,900.00
By:
, Published: Aug-2011

The pharmaceutical industry is facing change on a monumental scale. Patents on key products are expiring, the flow of new products from pipelines is low, and the number of decision makers involved has increased. Add to this mix Health Care Reform and the way a company develops, markets, and sells their products is impacted on some level. The next 5 – 10 years will be an exciting time to be a part of this industry as it undergoes a transformati.....

CBR Pharma Insights: Pharmaceutical Cliff Diving - Assessing the Key Challenges that will Re-shape the Industry

$3,900.00
By:
, Published: Jul-2011

In a challenging period for the pharmaceutical industry, first quarter results show an interesting picture. The generics industry, unsurprisingly, showed strong growth; lacking the impact of the patent cliff, the biotech industry also grew. For big pharma, sales were flat to negative for most, but a number of companies found that their work to streamline and restructure were showing positive results, with Q1 profits up.

The industry face.....

CBR Pharma Insights: The Coming Age of Biosimilars - Regulatory Developments and alliance Strategies Intensify Interest in a Developing Market

$3,900.00
By:
, Published: May-2011

Biosimilars are attracting significant attention at present as companies from all sectors of the biopharmaceutical market are investigating the opportunities they present.

Opinion is split as to the true potential of this market with some predicting it will grow to the multi-billion dollar level within five years, while others point to the limited impact of biosimilars in Europe to date to suggest that it will never be a major threat to .....

CBR Pharma Insights: New Product Launch Strategies - Initiating Market Entry with Sound Strategies and Tactics

$3,900.00
By:
, Published: Apr-2011

Product launch strategies and tactics are the keys to a successful market entry and can impact product performance for years down the road.

The launch of a product on a strong trajectory can mean exponential growth; however lost opportunities at the entry of a product to a market can necessitate re- launch and re-branding activities which can be costly and cumbersome. Additionally, these “Plan B” tactics are not always effective. Success.....